Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs: A report from the Swiss Blood Stem Cell Transplantation and Cellular Therapy Group (original) (raw)

Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 154 No. 5 (2024)

Summary

AIM: Until the year 2000, allogeneic haematopoietic cell transplantation (HCT) was the standard treatment for young and fit chronic myeloid leukaemia (CML) patients. CML was the main indication for allogeneic HCT. The introduction of tyrosine kinase inhibitors changed the treatment of CML patients dramatically. Allogeneic HCT was rapidly replaced by tyrosine kinase inhibitors as first-line treatment for CML, and the indication shifted to the treatment of non-responders, patients intolerant to tyrosine kinase inhibitors and patients whose CML is transforming to the accelerated phase and blast crisis. This paper describes changes in the use of transplantation technology for CML patients in the face of rapid drug development.

METHODS: All patients receiving a transplant for CML between 1997 and 2021 in Switzerland were included in the study. For the purpose of this analysis, time periods were analysed in quinquennia, 1997–2001 (Q1), 2002–2006 (Q2), 2007–2011 (Q3), 2012–2016 (Q4) and 2017–2021 (Q5), as the observation period spanned 25 years.

RESULTS: Overall, 239 patients received a transplant. These included 96 in Q1, 56 in Q2, 25 in Q3, 34 in Q4 and 28 in Q5. Patient characteristics changed over time: recent patients were older and had a longer interval from diagnosis to transplantation because of tyrosine kinase inhibitor treatment. However, the proportions of patients receiving transplants during an early versus advanced disease stage differed little. Transplant technology changed, as well. Patients received intensive conditioning regimens less often due to higher age and more commonly had peripheral blood as opposed to bone marrow transplants. However, the type of stem cell donor selected did not differ. In a univariable analysis, there were no significant differences in survival, progression-free survival, non-relapse mortality, relapse incidence or incidences of acute and chronic graft-versus-host disease among the five quinquennia. In a multivariable analysis, older age, donors other than HLA-identical siblings and more advanced disease stage, but not the quinquennium, were associated with higher risk of death.

CONCLUSION: Since the introduction of tyrosine kinase inhibitors haematopoietic cell transplantation has been used less frequently to treat CML. Patients in recent cohorts received transplants at an older age and later in the disease course; despite these higher risks, the outcome of allogeneic HCT has not worsened over time but has not improved, either. As the outcome is worse in advanced phases, it is important to conduct transplants before disease progression. Therefore, patients with advanced disease should be monitored closely and receive transplants in time.

References

  1. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984 Mar;1(8378):665–8. 10.1016/S0140-6736(84)92179-2 DOI: https://doi.org/10.1016/S0140-6736(84)92179-2
  2. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al.; IRIS Investigators. Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 Mar;376(10):917–27. 10.1056/NEJMoa1609324 DOI: https://doi.org/10.1056/NEJMoa1609324
  3. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 Mar;93(3):442–59. 10.1002/ajh.25011 DOI: https://doi.org/10.1002/ajh.25011
  4. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan;117(4):1141–5. 10.1182/blood-2010-03-277152 DOI: https://doi.org/10.1182/blood-2010-03-277152
  5. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr;123(15):2317–24. 10.1182/blood-2013-10-532341 DOI: https://doi.org/10.1182/blood-2013-10-532341
  6. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr;119(15):3403–12. 10.1182/blood-2011-11-390120 DOI: https://doi.org/10.1182/blood-2011-11-390120
  7. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun;362(24):2260–70. 10.1056/NEJMoa1002315 DOI: https://doi.org/10.1056/NEJMoa1002315
  8. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al.; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun;362(24):2251–9. 10.1056/NEJMoa0912614 DOI: https://doi.org/10.1056/NEJMoa0912614
  9. Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017 Jan;35(3):298–305. 10.1200/JCO.2016.68.2914 DOI: https://doi.org/10.1200/JCO.2016.68.2914
  10. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun;109(11):4686–92. 10.1182/blood-2006-11-055186 DOI: https://doi.org/10.1182/blood-2006-11-055186
  11. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, et al.; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010 Mar;115(10):1880–5. 10.1182/blood-2009-08-237115 DOI: https://doi.org/10.1182/blood-2009-08-237115
  12. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al.; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022 Aug;57(8):1217–39. 10.1038/s41409-022-01691-w DOI: https://doi.org/10.1038/s41409-022-01691-w
  13. Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, et al.; SAKK; German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562–9. 10.1038/leu.2015.281
  14. Chalandon YS, Bianchi G, Gras L, Koster L, Apperley J, Byrne J, et al. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol. 2022 Oct; Online ahead of print. DOI: https://doi.org/10.1002/ajh.26764

Most read articles by the same author(s)